Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
sábado, noviembre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Acadia Pharmaceuticals Inc
ACAD
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$17.11
-0.48
-2.73%
al cierre: Nov 20, 4:00 PM EST
$17.12
0.01
0.06%
After hour: 4:48 PM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Acadia Pharmaceuticals Financials
Acadia Pharmaceuticals (ACAD) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
ACADIA Pharmaceuticals Narrows FY2026 Sales Guidance from $1.240B-$1.300B to $1.265B-$1.295B vs $1.272B Est
ACADIA Pharmaceuticals (NASDAQ:ACAD) narrows FY2026 sales outlook from $1.240 billion-$1.300 billion to $1.265 billion-$1.295 billion vs $1.272 billion estimate.
Benzinga Newsdesk
PRO
ACADIA Pharmaceuticals Q3 EPS $0.31 Beats $0.20 Estimate, Sales $342.291M Beat $332.468M Estimate
Benzinga Newsdesk
PRO
ACADIA Pharmaceuticals Raises FY2026 Sales Guidance from $1.220B-$1.280B to $1.240B-$1.300B vs $1.242B Est
ACADIA Pharmaceuticals (NASDAQ:ACAD) raises FY2026 sales outlook from $1.220 billion-$1.280 billion to $1.240 billion-$1.300 billion vs $1.242 billion estimate.
Benzinga Newsdesk
PRO
ACADIA Pharmaceuticals Q2 EPS $0.18 Beats $0.07 Estimate, Sales $307.959M Beat $295.857M Estimate
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.07 by 157.14 percent. This is a 12.5 percent increase over earnings of $0.16 per share
Benzinga Newsdesk
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
ACADIA Pharmaceuticals Affirms FY2026 Sales Guidance of $1.220B-$1.280B vs $1.247B Est
ACADIA Pharmaceuticals (NASDAQ:ACAD) affirms FY2026 sales outlook from $1.220 billion-$1.280 billion to $1.220 billion-$1.280 billion vs $1.247 billion estimate.
Benzinga Newsdesk